Sands Capital Ventures

Sands Capital Ventures is a venture capital firm based in Arlington, Virginia, focused on investing in innovative businesses within the life sciences, technology, and global consumer sectors. Established in 2014 as a subsidiary of Sands Capital Management, the firm aims to identify and support entrepreneurs who have the potential to transform their industries through innovative solutions. With a strong emphasis on growth, Sands Capital Ventures engages in various stages of investment, including early and late venture financing, to foster the development of high-potential companies. The firm leverages its extensive industry expertise and global diligence capabilities to back entrepreneurs in their mission to drive impactful change.

Andrew P. Giordano

Senior Director of Client Relations

Sunil H. Thakor

Sr. Portfolio Manager

176 past transactions

HUNGRY

Series C in 2021
Hungry Marketplace, Inc. operates a mobile food marketplace that connects foodies with local chefs. The company offers HUNGRY, a marketplace that allows user to search and order made-to-order meals prepared by local chefs. It delivers fresh-cooked meals to foodies across District of Columbia, Maryland, and Virginia. The company was founded in 2016 and is based in Arlington, Virginia.

Upgrade

Series F in 2021
Upgrade is a neobank that offers credit to mainstream consumers through cards and personal loans, together with free credit monitoring and education tools that help consumers understand and manage their finances. Upgrade Card provides an innovative credit card that brings the low cost and responsible credit of installment lending to millions of retail locations in the U.S., while Upgrade Account is a mobile banking product offered to mainstream consumers.

Health Catalyst

Series D in 2015
Catalyst is solving healthcare data warehouse issues for some of the nation’s top health systems. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Catalyst helps organize, normalize, and link the data from all different systems. And they make it searchable by all users, even the non-technical, by using rich metadata capabilities.

Primer

Series C in 2021
Primer Technologies, Inc. develops software that uses machine learning techniques to help parse and collate a large number of documents across several languages. The company's systems read documents, discover insights, and automatically generate reports comparable to those of a human analyst. It helps governments and corporations monitor and understand the world’s information. Primer Technologies, Inc. was incorporated in 2014 and is based in San Francisco, California.

Elephas

Series A in 2021
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

LimaCharlie

Seed Round in 2022
Security Infrastructure as a Service (SIaaS). LimaCharlie abstracts away the hard parts of information security and delivers them on-demand (or à la carte) at scale in a manner similar to any major cloud provider drastically reducing costs and effort. We supply all the tools to run an MSSP or SOC as well as providing API’s that allow users to build and monetize their own products.

Bridgit

Private Placement in 2019
Bridgit Inc. develops and provides construction-project management solutions. The company offers Bridgit Bench, a construction resource planning and workforce management tool; and Bridgit Field, an inspection, task, and communication management solution. It caters to contractors and developers. Bridgit Inc. was incorporated in 2014 and is headquartered in Kitchener, Canada.

Mekonos

Series A in 2021
Mekonos Inc. engages in the design, development, and production of gene and cell therapies. The company develops integrated system-on-a-chip to develop predictive models for discovery and development. It develops MEMS, a technology that allows controlling individual nanoneedles to inject single cells, in a parallel architecture. Also, the company operates a cell-engineering platform. The company was founded in 2017 and is based in San Francisco, California

Nubank

Series G in 2021
Nubank issues, administrate, processes, and transfers payments related to post-paid credit cards and equity investment in other entities. It serves clients in Brazil. The company launched its proprietary loyalty rewards program ("Nubank Rewards"), as well as a digital account ("NuConta") that is already used by more than 17 million people. In Cristina Junqueira, David Velez, and Edward Wible founded EO2 Solucoes de Pagamento on May 6, 2013 that became Nubank in on June 25, 2013. It has its headquarters in São Paulo in Brazil.

Qvella Corporation

Venture Round in 2021
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Qvella Corporation

Venture Round in 2019
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Inspirna

Series D in 2022
Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating the first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease.

Scopely

Series D in 2019
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Day Zero Diagnostics

Venture Round in 2022
Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

Prilenia

Series B in 2021
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

Freenome

Series D in 2021
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Bridgit

Series B in 2021
Bridgit Inc. develops and provides construction-project management solutions. The company offers Bridgit Bench, a construction resource planning and workforce management tool; and Bridgit Field, an inspection, task, and communication management solution. It caters to contractors and developers. Bridgit Inc. was incorporated in 2014 and is headquartered in Kitchener, Canada.

JumpCloud

Series F in 2021
JumpCloud enables IT to securely manage user identities and connect them to resources regardless of provider, protocol, vendor, or location. JumpCloud is the first Directory-as-a-Service (DaaS), Active Directory, and LDAP reimagined. It centralizes and simplifies identity management and gives users one set of credentials to securely access their systems, apps, networks, and file servers – regardless of platform, protocol, provider, or location.

Codoxo

Series B in 2022
FraudScope, Inc. develops artificial intelligence (AI) based platform for healthcare fraud, waste, and abuse applications. It offers FraudScope, a software platform to detect, score, and rank suspect medical billing practices; and augment existing methodologies using sophisticated algorithm tuning to detect fraud schemes in raw claims data. The company’s platform also scans medical insurance claims data and creates real-time profiles for each provider, provider type, beneficiary, diagnosis, service profile, and care pathway; aggregates substantiated evidence for the fraud it detects; and ensures that healthcare dollars go to real patient care. FraudScope, Inc. was founded in 2016 and is based in Atlanta, Georgia.

Vesper

Venture Round in 2021
Vesper Technologies Inc. develops and manufactures piezoelectric MEMS microphones. It offers its products for various microphone array applications in mobile handsets, tablets, and other products. The company was formerly known as Sonify. The company was founded in 2009 and is based in Boston, Massachusetts.

SafeRide, Inc

Series B in 2021
SafeRide focuses on providing patients with transportation services to attend their health appointments in time. SafeRide provides healthcare providers with solutions to send text alerts about appointments and track the rides of their patients. SafeRide was founded by Whit Schrader and Robbins Schrader in April 2015.

Day Zero Diagnostics

Private Placement in 2018
Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

RayzeBio

Series D in 2022
RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Paydiant

Series B in 2012
Paydiant, Inc. provides a cloud-based white label mobile wallet platform. The company’s platform enables merchants, banks, and partners to integrate mobile payments, offers, loyalty, and ATM cash access into their own branded mobile app. It offers its solutions through resellers and distributors. The company was incorporated in 2010 and is based in Auburndale, Massachusetts. As of April 2, 2015, Paydiant, Inc. operates as a subsidiary of PayPal Holdings, Inc.

Dice Therapeutics

Series C in 2021
DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Boom Fantasy

Venture Round in 2021
Boom Sports is a technology company whose mission is to entertain and connect sports fans through games. After building the most popular real-money pick 'em daily fantasy product (2-time EGR app of the year), we're designing and operating world-class, free-to-play, games for media, league, and pro sports team partners. Our flagship product is NBC Sports Predictor, which offers fans in all 50 states the chance to win real money based on their (free) predictions. The product has been a huge success -- hundreds of thousands of active users, a 4.8 app store rating on 2K+ reviews -- and has provided a model for others that want to maximize the value of their audience in advance of legalized sports betting. If you want to build (legal) sports gaming products for the next generation of fans, come join us! We're hiring!

Dice Therapeutics

Series C in 2021
DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

ArcherDX

Private Placement in 2019
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.

Tellius

Series A in 2021
Tomorrow's Insights Today: Spend less time on reporting and more time on executing. We built Tellius to make big data simple for the modern workforce. Cut through swathes of information and find the answers you’re looking for whether you’re an IT pro, marketing guru or C-level exec. Tellius extends traditional self-service BI concepts through the use search-enabled visualizations and a proprietary recommendation engine that automates the basic interpretation and analysis of data. Using machine learning, Tellius analyzes data to find hidden correlations, trends and anomalies which are then presented as a set of suggested visualizations and predictive models. Unlike traditional BI tools, Tellius is built on a distributed architecture (Apache Spark) which provides the scale and performance required for Big Data environments.

Freenome

Private Placement in 2020
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Complete Genomics

Series E in 2010
Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

BYJU'S

Private Equity Round in 2020
BYJU’S is a valuable ed-tech company at USD 10.5 billion and the creator of India’s most loved school learning app which offers highly adaptive, engaging, and effective learning programs for students in classes 1 -12 and competitive exams like JEE, NEET, CAT, and IAS. BYJU'S launched its flagship product, BYJU’S - The Learning App, for classes 4-12 in 2015. Today, the app has over 42 million registered students. With an average time of 71 minutes being spent by a student on the app every day from 1700+ cities, the app is creating a whole new way of learning through visual lessons. The Disney. BYJU'S Early Learn App was launched in June 2019, a special offering from BYJU'S for students in classes 1-3 featuring Disney’s timeliness characters. In early 2019, BYJU'S also acquired Osmo, a Palo Alto-based maker of educational games to transform the whole offline to an online learning experience.

908 Devices

Series E in 2019
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.

Freenome

Series C in 2020
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Farcast

Series B in 2016
Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

Totient

Seed Round in 2020
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.

Scopely

Private Placement in 2017
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Karuna Therapeutics

Series B in 2019
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer’s, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.

Bridgit

Private Placement in 2020
Bridgit Inc. develops and provides construction-project management solutions. The company offers Bridgit Bench, a construction resource planning and workforce management tool; and Bridgit Field, an inspection, task, and communication management solution. It caters to contractors and developers. Bridgit Inc. was incorporated in 2014 and is headquartered in Kitchener, Canada.

Spruce Biosciences

Private Placement in 2020
Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Totient

Private Placement in 2020
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.

BigBasket

Venture Round in 2017
BigBasket is an online food and grocery store that delivers personal and household needs right to customers' doorstep. The company believes in being smart, quick, and efficient making life as leisurely as possible. Customers can browse through the vast range of products at bigbasket.com, order, and get them to be delivered at the customers' own convenient time slot. The company handpicks each and every product, putting it through a safety packaging process, and delivering to customers' home.

Farcast

Series C in 2018
Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

Teckro

Series B in 2017
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.

DoorDash

Series G in 2019
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and dashers in the United States and internationally. It operates DoorDash marketplace, which provides an array of services that enable merchants to solve mission-critical challenges, such as customer acquisition, delivery, insights and analytics, merchandising, payment processing, and customer support; and offers DoorDash Drive, a white-label logistics service. The company was formerly known as Palo Alto Delivery Inc. and changed its name to DoorDash, Inc. in 2015. DoorDash, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Bridgit

Series A in 2019
Bridgit Inc. develops and provides construction-project management solutions. The company offers Bridgit Bench, a construction resource planning and workforce management tool; and Bridgit Field, an inspection, task, and communication management solution. It caters to contractors and developers. Bridgit Inc. was incorporated in 2014 and is headquartered in Kitchener, Canada.

Quad Technologies

Series A in 2015
Quad Technologies is disrupting cell separation and cell therapy workflows by providing researchers with a simple, cell-friendly capture and release technology for cell isolation. Their new MagCloudz™ Streptavidin Cell Separation kit, featuring novel QuickGel™ technology platform, enables straightforward, scalable and fast cell separation with unique magnetic particle dissociation, resulting in complete label free cells. For applications such as T Cell purification, stem cell isolation, circulating tumor cell (CTC) separation and immunotherapy, this unique solution offers drastically improved cell viability, purity and recovery while maintaining a native cellular phenotype.

Funding Circle

Series E in 2015
When Funding Circle was founded, they could see that businesses weren’t being given the finance to grow, while investors were making poor returns. They had a simple idea — let them support each other. By lending directly to businesses through Funding Circle, investors can now earn attractive returns to better provide for their future. Businesses get fast, easy access to funding to grow, create jobs, support local communities and drive the economy forward. They believe it’s better for everyone.

Genometry

Series A in 2012
Genometry, Inc. operates as a platform-technology company that gene-expression profiling solutions for pharmaceutical discovery applications. It produces gene-expression profiles from crude cell lysates in well plate format. The company’s biomedical-research community also engages in drug-discovery activities. It offers data-generation and primary analysis solutions to the pharmaceutical and biotechnology industries, non-profit organizations, and academic researchers. Genometry, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

DocuSign

Series F in 2015
DocuSign, Inc. provides cloud based transaction products and services in the United States. The company offers e-signature solution that enables businesses to digitally prepare, execute, and act on agreements. It serves large enterprises, sole proprietorships, small- to medium-sized businesses, professionals, and individuals. The company was 2003 and is headquartered in San Francisco, California.

Betable

Series A in 2013
Betable is the world’s first platform that enables any developer to legally offer real-money play in their games and apps on any platform or device. Betable is licensed by the United Kingdom Gambling Commission and Alderney Gambling Control Commission to offer support and infrastructure to developers to legally integrate real-money gambling into their mobile and social games and applications. Betable provides world-leading security, fraud protection, player location, identity and age verification and account monitoring to keep players’ funds safe and to ensure responsible gaming. Betable was founded in 2008 in London, United Kingdom. It also is headquartered in San Francisco, California.

HUNGRY

Series A in 2019
Hungry Marketplace, Inc. operates a mobile food marketplace that connects foodies with local chefs. The company offers HUNGRY, a marketplace that allows user to search and order made-to-order meals prepared by local chefs. It delivers fresh-cooked meals to foodies across District of Columbia, Maryland, and Virginia. The company was founded in 2016 and is based in Arlington, Virginia.

Teckro

Series C in 2019
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.

Acumen Pharmaceuticals

Private Placement in 2018
Acumen Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics and diagnostics for treating Alzheimer’s disease and related neurodegenerative conditions. The company focuses on developing ADDL-Select antibodies that target soluble Aß oligomers, which are main causes in the disease process. It also uses a sensitivity assay to measure soluble Aß oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials. Acumen Pharmaceuticals, Inc. was founded in 1996 and is based in Livermore, California.

SeLux Dx

Private Placement in 2018
SeLux Diagnostics, Inc. develops a next generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious disease. It develops a synthetic amplifier technology equipment that breaks the speed versus complexity tradeoff in AST testing and dramatically improves patient care. SeLux Diagnostics, Inc. was founded in 2014 and is based in Charlestown, Massachusetts.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.

Bridgit

Private Placement in 2018
Bridgit Inc. develops and provides construction-project management solutions. The company offers Bridgit Bench, a construction resource planning and workforce management tool; and Bridgit Field, an inspection, task, and communication management solution. It caters to contractors and developers. Bridgit Inc. was incorporated in 2014 and is headquartered in Kitchener, Canada.

Health Catalyst

Private Placement in 2019
Catalyst is solving healthcare data warehouse issues for some of the nation’s top health systems. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Catalyst helps organize, normalize, and link the data from all different systems. And they make it searchable by all users, even the non-technical, by using rich metadata capabilities.

Neptune Financial Inc.

Private Placement in 2018
Neptune Financial Inc. is a private equity firm specializing in buyouts, strategic acquisitions, refinancing, recapitalizations and growth capital in lower middle market. The firm provides senior secured term loans with recurring revenue lines. The frim is industry agnostic but it typically invests in business services, financial services, consumer, healthcare, TMT and industrials sectors. It invests in US based companies Non-Sponsored & Sponsored. The firm invests up to $30 million in companies with revenues starting $5 million and above and has EBTIDA of $2 million plus or plan to achieve profitability. It prefers to take majority stake in companies. The firm holds the investment for 3-6 year term. Neptune Financial Inc. was founded in 2017 and is headquartered in San Francisco, California.
Zinka Logistics Solutions Private Limited develops and operates an online trucking platform that connects shippers and truckers. Its platform enables truckers to book a load and move at capacity; and shippers of various sizes to have access to the truck at the specific time. Zinka Logistics Solutions Private Limited was formerly known as Blackbuck. The company was founded in 2015 and is based in Bengaluru, India.

Scopely

Series C in 2017
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Upgrade

Series C in 2018
Upgrade is a neobank that offers credit to mainstream consumers through cards and personal loans, together with free credit monitoring and education tools that help consumers understand and manage their finances. Upgrade Card provides an innovative credit card that brings the low cost and responsible credit of installment lending to millions of retail locations in the U.S., while Upgrade Account is a mobile banking product offered to mainstream consumers.

Thrive Earlier Detection

Series B in 2020
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Shine Analytics Limited

Private Placement in 2019
Shine Analytics Limited develops a hosted platform for managing and controlling external legal costs. Its platform helps in-house counsel teams to navigate the new legal market reality. The company was founded in 2014 and is based in Dublin, Ireland.

Scopely

Series B in 2016
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Scopely

Series E in 2020
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Brightflag

Series B in 2020
Brightflag enables organizations to take control of their legal spend with AI-powered software that’s easy to use and backed by proactive customer support. Brightflag processes billions of dollars of legal spend annually on behalf of its customers, resulting in hundreds of millions of dollars in savings and tens of thousands of hours in avoided administrative work. Founded in 2014, Brightflag serves a global community of in-house legal teams and their vendors from its offices in Dublin, New York, and Sydney.

Coagulo Medical Technologies

Venture Round in 2020
Coagulo Medical Technologies, Inc. develops testing systems that detects, identifies, and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers. The company is based in Auburndale, Massachusetts.

SeLux Dx

Venture Round in 2024
SeLux Diagnostics, Inc. develops a next generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious disease. It develops a synthetic amplifier technology equipment that breaks the speed versus complexity tradeoff in AST testing and dramatically improves patient care. SeLux Diagnostics, Inc. was founded in 2014 and is based in Charlestown, Massachusetts.

HealthSnap

Series B in 2024
HealthSnap is a remote patient monitoring platform for virtual chronic disease management. By making personalized and actionable health data accessible to everyone, HealthSnap empowers people living with chronic conditions anytime, anywhere. The company combines a comprehensive Remote Patient Monitoring Platform with remote care services that make it simple and profitable for healthcare organizations to improve patient outcomes, reduce readmissions, and lower the cost of care with virtual chronic disease management programs.

Elephas

Series C in 2023
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

Freenome

Series E in 2024
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Elephas

Series C in 2024
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

Ramp

Series D in 2023
Ramp Business Corporation offers a corporate credit card for businesses and startups. Its card enables to provide tracking and insight tools for founders and finance teams; and offers cash back on by using the card at various retailers that accept Visa and online. The company was incorporated in 2019 and is based in New York, New York.

Beta Bionics

Series D in 2023
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.

SafeRide, Inc

Series C in 2023
SafeRide focuses on providing patients with transportation services to attend their health appointments in time. SafeRide provides healthcare providers with solutions to send text alerts about appointments and track the rides of their patients. SafeRide was founded by Whit Schrader and Robbins Schrader in April 2015.

HUNGRY

Series C in 2023
Hungry Marketplace, Inc. operates a mobile food marketplace that connects foodies with local chefs. The company offers HUNGRY, a marketplace that allows user to search and order made-to-order meals prepared by local chefs. It delivers fresh-cooked meals to foodies across District of Columbia, Maryland, and Virginia. The company was founded in 2016 and is based in Arlington, Virginia.

Snyk

Series G in 2022
Snyk enables users to detect, fix, and prevent known vulnerabilities in third-party code modules, including Node

Tellius

Series B in 2022
Tomorrow's Insights Today: Spend less time on reporting and more time on executing. We built Tellius to make big data simple for the modern workforce. Cut through swathes of information and find the answers you’re looking for whether you’re an IT pro, marketing guru or C-level exec. Tellius extends traditional self-service BI concepts through the use search-enabled visualizations and a proprietary recommendation engine that automates the basic interpretation and analysis of data. Using machine learning, Tellius analyzes data to find hidden correlations, trends and anomalies which are then presented as a set of suggested visualizations and predictive models. Unlike traditional BI tools, Tellius is built on a distributed architecture (Apache Spark) which provides the scale and performance required for Big Data environments.

Vitara Biomedical

Series B in 2022
Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.

Red Sift

Series B in 2022
Founded by some of the people behind Shazam and backed by the most experienced entrepreneurs and angels in London, Red Sift exists to democratise the technology essential for cybersecurity. With the best estimate suggesting it's 400 times cheaper to launch a cyber attack than it is to defend against one. Red Sift wants to change the economics of this model and enable all organisations to defend themselves against the daily onslaught. Our Red Sift Open Cloud is a data analysis platform that is purpose-built for the challenges of cybersecurity. By harnessing the power of AI we can securely collate, compute & visualise data from thousands of individual signals to help organizations to optimise their cybersecurity. The first product on the Red Sift platform is OnDMARC, a SaaS product that helps organisations to implement and maintain DMARC. This email authentication protocol effectively blocks phishing attacks and increases the deliverability of genuine emails.

Papercup

Series A in 2022
Papercup develops a software which automatically translates voice track in videos based on the combinations of bayesian neural networks and speech synthesis. The software helps the video creators to produce a video in their original language and any user can translate that video in their preferred language. The company is based in London, United Kingdom.

Exo

Series C in 2021
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.

Allvision

Seed Round in 2019
Allvision IO, Inc. develops platform that aggregates multiple sources of 3 dimensional data. The platform backed by machine learning and cloud computing provides analysis to derive actionable information. Allvision IO, Inc. provides asset detection and tracking; mobility maps; and compliance information to users. It caters to transportation, engineering, infrastructure, government, and insurance industry. The company was founded in 2017 and is headquartered in Pittsburgh, Pennsylvania.

Totient

Seed Round in 2020
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.

Blackbuck

Series C in 2017
Keeping technology at the core, Zinka Logistics is redefining the logistics landscape of India, making it reliable and efficient. Our comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Zinka Logistics marks the beginning.

WireWheel

Series A in 2018
WireWheel, Inc. develops a data privacy management platform that helps comply with data privacy and data protection regulations. The company’s platform complies with regulations, including the EU GDPR, Privacy Shield, PCI DSS, and HIPAA. Its products include privacy program management and subject rights request management. The company combines machine learning, data science, and cloud computing. WireWheel, Inc. was incorporated in 2016 and is based in Arlington, Virginia

Avitide

Series E in 2017
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Credo AI

Series A in 2022
Developer of artificial intelligence platform intended to develop AI with the highest ethical standards. The company's SaaS platform provides continuous and comprehensive AI governance to measure, monitor, and manage AI-introduced risks at scale, enabling enterprises to build customer trust to unlock sales opportunities, differentiate with AI, and manage AI risks effectively to gain confidence in their AI deployments.

Acrivon Therapeutics

Series B in 2021
Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success.

Samumed, LLC

Venture Round in 2021
Samumed, LLC is engaged in small molecule drug development using assays and screens for the treatment of oncology and degenerative diseases. Its product includes SM04690, a small molecule inhibitor of the Wnt pathway that is administered as an intra-articular injection for treatment of osteoarthritis of the knee; and SM07883, a small-molecule designed to reduce disease pathology. The company was known as Wintherix & Epitherix, LLC. Samumed, LLC was founded in 2007 and is based in San Diego, California.

Scopely

Series A in 2014
Scopely, Inc. develops mobile and tablet touchscreen-based games for casual and core gamers worldwide. It offers fleet command games; and game design, live, marketing, analytics, business development, advertising, and other services. Scopely, Inc. was founded in 2011 and is based in Culver City, California.

Vesper

Series B in 2018
Vesper Technologies Inc. develops and manufactures piezoelectric MEMS microphones. It offers its products for various microphone array applications in mobile handsets, tablets, and other products. The company was formerly known as Sonify. The company was founded in 2009 and is based in Boston, Massachusetts.

Acumen Pharmaceuticals

Series A in 2018
Acumen Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics and diagnostics for treating Alzheimer’s disease and related neurodegenerative conditions. The company focuses on developing ADDL-Select antibodies that target soluble Aß oligomers, which are main causes in the disease process. It also uses a sensitivity assay to measure soluble Aß oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials. Acumen Pharmaceuticals, Inc. was founded in 1996 and is based in Livermore, California.